{"original": "The review includes 26 trials comparing salmeterol to placebo and eight trials comparing with salbutamol. These included 62,815 participants with asthma (including 2,599 children). In six trials (2,766 patients), no serious adverse event data could be obtained. All-cause mortality was higher with regular salmeterol than placebo but the increase was not significant (Peto odds ratio (OR) 1.33 (95% CI 0.85 to 2.08)). Non-fatal serious adverse events were significantly increased when regular salmeterol was compared with placebo (OR 1.15 95% CI 1.02 to 1.29). One extra serious adverse event occurred over 28 weeks for every 188 people treated with regular salmeterol (95% CI 95 to 2606). There is insufficient evidence to assess whether the risk in children is higher or lower than in adults. We found no significant increase in fatal or non-fatal serious adverse events when regular salmeterol was compared with regular salbutamol. We combined individual patient data from the two largest studies (SNS: n=25,180 and SMART: n=26,355), as all the asthma-related deaths in adults occurred in these studies. In patients who were not taking inhaled corticosteroids, compared to regular salbutamol or placebo, there was a significant increase in risk of asthma-related death with regular salmeterol (Peto OR 6.15 95% CI 1.73 to 21.84). The confidence interval for patients who were taking inhaled corticosteroids is wide and cannot rule in or out an increase in asthma mortality in the presence of an inhaled corticosteroid (Peto OR 2.03 95% CI 0.82 to 5.00). In comparison with placebo, we have found an increased risk of serious adverse events with regular salmeterol. There is also a clear increase in risk of asthma-related mortality in patients not using inhaled corticosteroids in the two large surveillance studies. Although the increase in asthma-related mortality was smaller in patients taking inhaled corticosteroids at baseline, the confidence interval is wide, so we cannot conclude that the inhaled corticosteroids abolish the risks of regular salmeterol. The adverse effects of regular salmeterol in children remain uncertain due to the small number of children studied.", "rating_type": "pairwise", "references": ["There was no statistically significant difference in the number of people who died during treatment with salmeterol compared with placebo or salbutamol. Because so few people die of asthma, huge trials or observational studies are normally required to detect a difference in death rates from asthma. There were more non-fatal serious adverse events in people taking salmeterol compared to those on placebo; for every 188 people treated with salmeterol for 28 weeks, one extra non-fatal event occurred in comparison with placebo. There was no significant differences in serious adverse events in people on salmeterol compared to regular salbutamol. In order to obtain individual patient data on asthma deaths, we looked separately at mortality in two large trials on over 51,000 patients who were not taking inhaled corticosteroids, and found that there was an increase in the number of asthma-related deaths among people on salmeterol. We conclude that, for patients whose asthma is not well-controlled on moderate doses of inhaled corticosteroids, additional salmeterol can improve symptoms but this may be at the expense of an increased risk of serious adverse events and asthma related mortality.\u00a0Salmeterol should not be used as a substitute for inhaled corticosteroids, and adherence with inhaled steroids should be kept under review if separate inhalers are used. Salmeterol should not be taken by people who are not taking regular inhaled steroids due to the increased risk of asthma-related death."], "simplification1": "The review includes 26 trials comparing salmeterol to placebo and eight trials comparing with salbutamol. These included 62,815 participants with asthma (including 2,599 children). In six trials (2,766 patients), no serious adverse event data could be obtained. There is insufficient evidence to assess whether the risk in children is higher or lower than in adults. We found no significant increase in fatal or non-fatal asthma-related serious adverse events when regular Salmeterol was compared with placebo. In comparison with placebo, we have found an increased risk of serious side effects. There was also a clear increase in the risk of death from asthma in patients who were not taking inhaled corticosteroids in the two large surveillance studies. We combined the data from the two largest studies (25,180 and 26,355 participants) as all the asthma--related deaths in adults occurred in these studies. In patients who did not take inhaled steroids, compared to patients taking regular salmetamol or placebo, there was an increase in risk of dying from asthma related to any cause. The confidence interval for this result is wide and we cannot rule in or out an increase of asthma deaths in the presence of an inhaled steroid. We cannot conclude that the use of regular salmeterot reduces the risks of asthma in children due to the small number of children studied.", "simplification2": "We found 26 studies (62,815 adults and 2,599 children) that compared salmeterol to placebo and eight studies (2,074 adults) that looked at salbutamol. We found that people who were not taking an inhaled corticosteroid were at significantly higher risk of death from any cause than those who were. There was no difference in the number of people who had a non-fatal event (such as a heart attack) or serious side effects with the inhaled steroids compared with the placebo. There were no differences in the numbers of patients who experienced a serious side effect with the steroids compared to those who did not. We were not able to combine data from the two largest studies (25,180 adults and 26,355 children) as all the deaths in adults were in the control group and we could not obtain all-cause deaths (i.e. death due to any cause). There was a clear increase in the risk of having a serious adverse event with regular salmetamol when compared to placebo. This was the case in both adults and children. We also found that there was an increased risk of serious adverse events with the regular salmyol group compared to the placebo group. We are unable to say whether the risk in children is higher or lower than in adults. There is not enough evidence to say which inhaled steroid is the best to use.", "system1": "bart-xsum", "system2": "UL", "ratings": [{"name": "readability", "type": "binary", "value": [1, 0, 0], "agg_value": 0, "agg_strategy": "majority"}]}
{"original": "The review includes 26 trials comparing salmeterol to placebo and eight trials comparing with salbutamol. These included 62,815 participants with asthma (including 2,599 children). In six trials (2,766 patients), no serious adverse event data could be obtained. All-cause mortality was higher with regular salmeterol than placebo but the increase was not significant (Peto odds ratio (OR) 1.33 (95% CI 0.85 to 2.08)). Non-fatal serious adverse events were significantly increased when regular salmeterol was compared with placebo (OR 1.15 95% CI 1.02 to 1.29). One extra serious adverse event occurred over 28 weeks for every 188 people treated with regular salmeterol (95% CI 95 to 2606). There is insufficient evidence to assess whether the risk in children is higher or lower than in adults. We found no significant increase in fatal or non-fatal serious adverse events when regular salmeterol was compared with regular salbutamol. We combined individual patient data from the two largest studies (SNS: n=25,180 and SMART: n=26,355), as all the asthma-related deaths in adults occurred in these studies. In patients who were not taking inhaled corticosteroids, compared to regular salbutamol or placebo, there was a significant increase in risk of asthma-related death with regular salmeterol (Peto OR 6.15 95% CI 1.73 to 21.84). The confidence interval for patients who were taking inhaled corticosteroids is wide and cannot rule in or out an increase in asthma mortality in the presence of an inhaled corticosteroid (Peto OR 2.03 95% CI 0.82 to 5.00). In comparison with placebo, we have found an increased risk of serious adverse events with regular salmeterol. There is also a clear increase in risk of asthma-related mortality in patients not using inhaled corticosteroids in the two large surveillance studies. Although the increase in asthma-related mortality was smaller in patients taking inhaled corticosteroids at baseline, the confidence interval is wide, so we cannot conclude that the inhaled corticosteroids abolish the risks of regular salmeterol. The adverse effects of regular salmeterol in children remain uncertain due to the small number of children studied.", "rating_type": "pairwise", "references": ["There was no statistically significant difference in the number of people who died during treatment with salmeterol compared with placebo or salbutamol. Because so few people die of asthma, huge trials or observational studies are normally required to detect a difference in death rates from asthma. There were more non-fatal serious adverse events in people taking salmeterol compared to those on placebo; for every 188 people treated with salmeterol for 28 weeks, one extra non-fatal event occurred in comparison with placebo. There was no significant differences in serious adverse events in people on salmeterol compared to regular salbutamol. In order to obtain individual patient data on asthma deaths, we looked separately at mortality in two large trials on over 51,000 patients who were not taking inhaled corticosteroids, and found that there was an increase in the number of asthma-related deaths among people on salmeterol. We conclude that, for patients whose asthma is not well-controlled on moderate doses of inhaled corticosteroids, additional salmeterol can improve symptoms but this may be at the expense of an increased risk of serious adverse events and asthma related mortality.\u00a0Salmeterol should not be used as a substitute for inhaled corticosteroids, and adherence with inhaled steroids should be kept under review if separate inhalers are used. Salmeterol should not be taken by people who are not taking regular inhaled steroids due to the increased risk of asthma-related death."], "simplification1": "The review includes 26 trials comparing salmeterol to placebo and eight trials comparing with salbutamol. These included 62,815 participants with asthma (including 2,599 children). In six trials (2,766 patients), no serious adverse event data could be obtained. There is insufficient evidence to assess whether the risk in children is higher or lower than in adults. We found no significant increase in fatal or non-fatal asthma-related serious adverse events when regular Salmeterol was compared with placebo. In comparison with placebo, we have found an increased risk of serious side effects. There was also a clear increase in the risk of death from asthma in patients who were not taking inhaled corticosteroids in the two large surveillance studies. We combined the data from the two largest studies (25,180 and 26,355 participants) as all the asthma--related deaths in adults occurred in these studies. In patients who did not take inhaled steroids, compared to patients taking regular salmetamol or placebo, there was an increase in risk of dying from asthma related to any cause. The confidence interval for this result is wide and we cannot rule in or out an increase of asthma deaths in the presence of an inhaled steroid. We cannot conclude that the use of regular salmeterot reduces the risks of asthma in children due to the small number of children studied.", "simplification2": "We found 26 trials comparing salmetol to placebo and eight trials comparing with salbutamol. These included 62,815 participants with asthma (2,599 children). In six trials (2.766 patients), no serious adverse events data could be obtained. We found no significant increase in fatal or non-fatal serious adverse event rates when regular salmeterol was compared with regular salbutamic acid. There was an increase in the risk of asthma-related death with regular Salmeterol compared to placebo. There is also an increase of asthma deaths in patients not taking inhaled corticosteroids in the two large surveillance studies. We cannot be sure whether regular salmetamol is better than placebo for reducing the risk for asthma- related deaths. There were no serious side effects of regular salmyol in children. The risk of serious side effect in children remains uncertain due to the small number of children studied. We combined the results of two large studies (26,355 participants) as all the asthma--related deaths in adults occurred in these studies. In patients who were not taking an inhaled steroid, compared to regular sal butamol or placebo, there was an increased risk of death from asthma. The confidence interval for patients who are taking an inhaler was wide and we cannot rule out an increase for asthma deaths. We have found an increased number of serious adverse effects with regular treatment with salmeterolin compared to a placebo. We are uncertain whether regular treatment is better or worse than taking an asthma inhaler.", "system1": "bart-xsum", "system2": "Decoder", "ratings": [{"name": "readability", "type": "binary", "value": [0, 0, 0], "agg_value": 0, "agg_strategy": "majority"}]}
{"original": "The review includes 26 trials comparing salmeterol to placebo and eight trials comparing with salbutamol. These included 62,815 participants with asthma (including 2,599 children). In six trials (2,766 patients), no serious adverse event data could be obtained. All-cause mortality was higher with regular salmeterol than placebo but the increase was not significant (Peto odds ratio (OR) 1.33 (95% CI 0.85 to 2.08)). Non-fatal serious adverse events were significantly increased when regular salmeterol was compared with placebo (OR 1.15 95% CI 1.02 to 1.29). One extra serious adverse event occurred over 28 weeks for every 188 people treated with regular salmeterol (95% CI 95 to 2606). There is insufficient evidence to assess whether the risk in children is higher or lower than in adults. We found no significant increase in fatal or non-fatal serious adverse events when regular salmeterol was compared with regular salbutamol. We combined individual patient data from the two largest studies (SNS: n=25,180 and SMART: n=26,355), as all the asthma-related deaths in adults occurred in these studies. In patients who were not taking inhaled corticosteroids, compared to regular salbutamol or placebo, there was a significant increase in risk of asthma-related death with regular salmeterol (Peto OR 6.15 95% CI 1.73 to 21.84). The confidence interval for patients who were taking inhaled corticosteroids is wide and cannot rule in or out an increase in asthma mortality in the presence of an inhaled corticosteroid (Peto OR 2.03 95% CI 0.82 to 5.00). In comparison with placebo, we have found an increased risk of serious adverse events with regular salmeterol. There is also a clear increase in risk of asthma-related mortality in patients not using inhaled corticosteroids in the two large surveillance studies. Although the increase in asthma-related mortality was smaller in patients taking inhaled corticosteroids at baseline, the confidence interval is wide, so we cannot conclude that the inhaled corticosteroids abolish the risks of regular salmeterol. The adverse effects of regular salmeterol in children remain uncertain due to the small number of children studied.", "rating_type": "pairwise", "references": ["There was no statistically significant difference in the number of people who died during treatment with salmeterol compared with placebo or salbutamol. Because so few people die of asthma, huge trials or observational studies are normally required to detect a difference in death rates from asthma. There were more non-fatal serious adverse events in people taking salmeterol compared to those on placebo; for every 188 people treated with salmeterol for 28 weeks, one extra non-fatal event occurred in comparison with placebo. There was no significant differences in serious adverse events in people on salmeterol compared to regular salbutamol. In order to obtain individual patient data on asthma deaths, we looked separately at mortality in two large trials on over 51,000 patients who were not taking inhaled corticosteroids, and found that there was an increase in the number of asthma-related deaths among people on salmeterol. We conclude that, for patients whose asthma is not well-controlled on moderate doses of inhaled corticosteroids, additional salmeterol can improve symptoms but this may be at the expense of an increased risk of serious adverse events and asthma related mortality.\u00a0Salmeterol should not be used as a substitute for inhaled corticosteroids, and adherence with inhaled steroids should be kept under review if separate inhalers are used. Salmeterol should not be taken by people who are not taking regular inhaled steroids due to the increased risk of asthma-related death."], "simplification1": "The review includes 26 trials comparing salmeterol to placebo and eight trials comparing with salbutamol. These included 62,815 participants with asthma (including 2,599 children). In six trials (2,766 patients), no serious adverse event data could be obtained. There is insufficient evidence to assess whether the risk in children is higher or lower than in adults. We found no significant increase in fatal or non-fatal asthma-related serious adverse events when regular Salmeterol was compared with placebo. In comparison with placebo, we have found an increased risk of serious side effects. There was also a clear increase in the risk of death from asthma in patients who were not taking inhaled corticosteroids in the two large surveillance studies. We combined the data from the two largest studies (25,180 and 26,355 participants) as all the asthma--related deaths in adults occurred in these studies. In patients who did not take inhaled steroids, compared to patients taking regular salmetamol or placebo, there was an increase in risk of dying from asthma related to any cause. The confidence interval for this result is wide and we cannot rule in or out an increase of asthma deaths in the presence of an inhaled steroid. We cannot conclude that the use of regular salmeterot reduces the risks of asthma in children due to the small number of children studied.", "simplification2": "The review includes 26 trials comparing salmeterol to placebo and eight trials comparing with salbutamol. These included 62,815 participants with asthma (including 2,599 children). In six trials (2,766 patients), no serious adverse event data could be obtained. We combined individual patient data from the two largest studies (SNS: 25,180 and SMART: 26,355), as all the asthma-related deaths in adults occurred in these studies. We found no significant increase in fatal or non-fatal serious adverse events when the two drugs were compared with each other. However, there was an increase in the risk of death from any cause (all-cause mortality) in patients treated with the drug, compared to placebo, but the increase was not significant (Peto odds ratio (OR) 1.33 (95% CI 0.85 to 2.08)). There is also a clear increase in risk of mortality in patients not using inhaled corticosteroids in the two large surveillance studies. The confidence interval for patients who were taking inhaled steroids is wide and cannot rule in or out an increase of asthma mortality in the presence of an inhaled steroid. Although the increase in deaths was smaller in patients taking inhalers at baseline, the confidence interval is wide, so we cannot conclude that the inhalers abolish the risks of the drug. In comparison with placebo, we have found an increased risk of serious side effects. One extra serious side effect occurred over 28 weeks for every 188 people treated with regular Salmeterol compared with placebo. There is insufficient evidence to assess whether the risk in children is higher or lower than in adults. The adverse effects in children remain uncertain due to the small number of children studied.", "system1": "bart-xsum", "system2": "NAPSS", "ratings": [{"name": "readability", "type": "binary", "value": [0, 0, 0], "agg_value": 0, "agg_strategy": "majority"}]}
{"original": "The review includes 26 trials comparing salmeterol to placebo and eight trials comparing with salbutamol. These included 62,815 participants with asthma (including 2,599 children). In six trials (2,766 patients), no serious adverse event data could be obtained. All-cause mortality was higher with regular salmeterol than placebo but the increase was not significant (Peto odds ratio (OR) 1.33 (95% CI 0.85 to 2.08)). Non-fatal serious adverse events were significantly increased when regular salmeterol was compared with placebo (OR 1.15 95% CI 1.02 to 1.29). One extra serious adverse event occurred over 28 weeks for every 188 people treated with regular salmeterol (95% CI 95 to 2606). There is insufficient evidence to assess whether the risk in children is higher or lower than in adults. We found no significant increase in fatal or non-fatal serious adverse events when regular salmeterol was compared with regular salbutamol. We combined individual patient data from the two largest studies (SNS: n=25,180 and SMART: n=26,355), as all the asthma-related deaths in adults occurred in these studies. In patients who were not taking inhaled corticosteroids, compared to regular salbutamol or placebo, there was a significant increase in risk of asthma-related death with regular salmeterol (Peto OR 6.15 95% CI 1.73 to 21.84). The confidence interval for patients who were taking inhaled corticosteroids is wide and cannot rule in or out an increase in asthma mortality in the presence of an inhaled corticosteroid (Peto OR 2.03 95% CI 0.82 to 5.00). In comparison with placebo, we have found an increased risk of serious adverse events with regular salmeterol. There is also a clear increase in risk of asthma-related mortality in patients not using inhaled corticosteroids in the two large surveillance studies. Although the increase in asthma-related mortality was smaller in patients taking inhaled corticosteroids at baseline, the confidence interval is wide, so we cannot conclude that the inhaled corticosteroids abolish the risks of regular salmeterol. The adverse effects of regular salmeterol in children remain uncertain due to the small number of children studied.", "rating_type": "pairwise", "references": ["There was no statistically significant difference in the number of people who died during treatment with salmeterol compared with placebo or salbutamol. Because so few people die of asthma, huge trials or observational studies are normally required to detect a difference in death rates from asthma. There were more non-fatal serious adverse events in people taking salmeterol compared to those on placebo; for every 188 people treated with salmeterol for 28 weeks, one extra non-fatal event occurred in comparison with placebo. There was no significant differences in serious adverse events in people on salmeterol compared to regular salbutamol. In order to obtain individual patient data on asthma deaths, we looked separately at mortality in two large trials on over 51,000 patients who were not taking inhaled corticosteroids, and found that there was an increase in the number of asthma-related deaths among people on salmeterol. We conclude that, for patients whose asthma is not well-controlled on moderate doses of inhaled corticosteroids, additional salmeterol can improve symptoms but this may be at the expense of an increased risk of serious adverse events and asthma related mortality.\u00a0Salmeterol should not be used as a substitute for inhaled corticosteroids, and adherence with inhaled steroids should be kept under review if separate inhalers are used. Salmeterol should not be taken by people who are not taking regular inhaled steroids due to the increased risk of asthma-related death."], "simplification1": "The review includes 26 trials comparing salmeterol to placebo and eight trials comparing with salbutamol. These included 62,815 participants with asthma (including 2,599 children). In six trials (2,766 patients), no serious adverse event data could be obtained. There is insufficient evidence to assess whether the risk in children is higher or lower than in adults. We found no significant increase in fatal or non-fatal asthma-related serious adverse events when regular Salmeterol was compared with placebo. In comparison with placebo, we have found an increased risk of serious side effects. There was also a clear increase in the risk of death from asthma in patients who were not taking inhaled corticosteroids in the two large surveillance studies. We combined the data from the two largest studies (25,180 and 26,355 participants) as all the asthma--related deaths in adults occurred in these studies. In patients who did not take inhaled steroids, compared to patients taking regular salmetamol or placebo, there was an increase in risk of dying from asthma related to any cause. The confidence interval for this result is wide and we cannot rule in or out an increase of asthma deaths in the presence of an inhaled steroid. We cannot conclude that the use of regular salmeterot reduces the risks of asthma in children due to the small number of children studied.", "simplification2": "The text discusses a review of 26 trials comparing salmeterol to placebo and eight trials comparing it to salbutamol, involving 62,815 participants with asthma, including 2,599 children. In six trials, no serious adverse event data was available. All-cause mortality was slightly higher with regular salmeterol than placebo, but not significantly. Non-fatal serious adverse events were significantly increased with regular salmeterol compared to placebo. There isn't enough evidence to determine the risk in children compared to adults. No significant increase in fatal or non-fatal serious adverse events was found when comparing regular salmeterol to regular", "system1": "bart-xsum", "system2": "GPT-4", "ratings": [{"name": "readability", "type": "binary", "value": [1, 1, 1], "agg_value": 1, "agg_strategy": "majority"}]}
{"original": "Six trials were identified, with 425 patients randomized to D-penicillamine and 258 to placebo. A statistically significant benefit was observed for D-penicillamine when compared to placebo for all three-dose ranges and for most outcome measures including: tender joint counts, pain, physician's global assessments and ESR. The standardized weighted mean differences between treatment and placebo in moderate doses were -0.51 [95% CI -0.88, -0.14] for tender joint counts, -0.56 (95% CI -0.87, -0.26) for pain and -0.97 (95% CI -1.25, -0.70) for global assessment. The difference for ESR was -10.6 mm/hr. Similar results were observed for the higher dose group. Total withdrawals were significantly higher in the moderate and high dosage D-penicillamine groups (OR=1.63 and 2.13 respectively), mostly due to increased adverse reactions (OR = 2.60 and 4.95 respectively), including renal and hematological abnormalities. D-penicillamine appears to have a clinically and statistically significant benefit on the disease activity of patients with rheumatoid arthritis. Its efficacy appears to be similar to that of other disease modifying anti-rheumatic drugs (DMARDs), but with a significantly higher toxicity. Its effects on long-term functional status and radiological progression are not clear from this review.", "rating_type": "pairwise", "references": ["Penicillamine is a penicillin derived compound. Studies showed that this could be used to treat rheumatoid arthritis originally in 1950. It was frequently used in the past, but its use has declined with the increasing use of other disease modifying anti-rheumatic drugs (DMARDs), such as methotrexate. The purpose of this summary was to find out if penicillamine is helpful in the treatment of rheumatoid arthritis. Penicillamine was seen to be beneficial for all ranges of dosages for disease activity on tender joint pain, physician global assessment and sed rate. No major differences were observed between placebo and low dose penicillamine (<500 mg/day). For higher dosages, patients on penicillamine were twice as likely to withdraw than those receiving placebo 500 to <1000 mg/day. D-penicillamine appears be have a clinical and statistical benefit on the disease activity of patients with rheumatoid arthritis. Its benefit is similar to that of other such drugs, such as disease modifying anti-rheumatic drugs (DMARDs). More adverse reactions are seen in patients being treated with D-penicillamine."], "simplification1": "This review of trials found that D-penicillamine appears to have a clinically and statistically significant benefit on the disease activity of patients with rheumatoid arthritis. Its efficacy appears to be similar to that of other disease modifying anti-rheumatic drugs (DMARDs), but with a significantly higher toxicity. Its effects on long-term functional status and radiological progression are not clear from this review.", "simplification2": "Six trials with 425 patients on D-penicillamine and 258 on placebo were found. D-penicillamine showed significant benefits in reducing joint pain, overall pain, and inflammation compared to placebo. However, more people withdrew from the study due to side effects, including kidney and blood issues. D-penicillamine seems effective for rheumatoid arthritis, but has higher toxicity than other similar drugs. Its long-term effects are still unclear.", "system1": "bart-xsum", "system2": "GPT-4", "ratings": [{"name": "readability", "type": "binary", "value": [1, 1, 1], "agg_value": 1, "agg_strategy": "majority"}]}
{"original": "Six trials were identified, with 425 patients randomized to D-penicillamine and 258 to placebo. A statistically significant benefit was observed for D-penicillamine when compared to placebo for all three-dose ranges and for most outcome measures including: tender joint counts, pain, physician's global assessments and ESR. The standardized weighted mean differences between treatment and placebo in moderate doses were -0.51 [95% CI -0.88, -0.14] for tender joint counts, -0.56 (95% CI -0.87, -0.26) for pain and -0.97 (95% CI -1.25, -0.70) for global assessment. The difference for ESR was -10.6 mm/hr. Similar results were observed for the higher dose group. Total withdrawals were significantly higher in the moderate and high dosage D-penicillamine groups (OR=1.63 and 2.13 respectively), mostly due to increased adverse reactions (OR = 2.60 and 4.95 respectively), including renal and hematological abnormalities. D-penicillamine appears to have a clinically and statistically significant benefit on the disease activity of patients with rheumatoid arthritis. Its efficacy appears to be similar to that of other disease modifying anti-rheumatic drugs (DMARDs), but with a significantly higher toxicity. Its effects on long-term functional status and radiological progression are not clear from this review.", "rating_type": "pairwise", "references": ["Penicillamine is a penicillin derived compound. Studies showed that this could be used to treat rheumatoid arthritis originally in 1950. It was frequently used in the past, but its use has declined with the increasing use of other disease modifying anti-rheumatic drugs (DMARDs), such as methotrexate. The purpose of this summary was to find out if penicillamine is helpful in the treatment of rheumatoid arthritis. Penicillamine was seen to be beneficial for all ranges of dosages for disease activity on tender joint pain, physician global assessment and sed rate. No major differences were observed between placebo and low dose penicillamine (<500 mg/day). For higher dosages, patients on penicillamine were twice as likely to withdraw than those receiving placebo 500 to <1000 mg/day. D-penicillamine appears be have a clinical and statistical benefit on the disease activity of patients with rheumatoid arthritis. Its benefit is similar to that of other such drugs, such as disease modifying anti-rheumatic drugs (DMARDs). More adverse reactions are seen in patients being treated with D-penicillamine."], "simplification1": "This review of trials found that D-penicillamine appears to have a clinically and statistically significant benefit on the disease activity of patients with rheumatoid arthritis. Its efficacy appears to be similar to that of other disease modifying anti-rheumatic drugs (DMARDs), but with a significantly higher toxicity. Its effects on long-term functional status and radiological progression are not clear from this review.", "simplification2": "Six randomised controlled trials were identified, with 425 patients randomized to D-penicillamine and 258 to placebo. A statistically significant benefit was observed when compared to placebo for all three-dose ranges and for most outcome measures including: tender joint counts, pain, physician's global assessments and ESR. The difference for ESR was -10.6 mm/hr. Similar results were observed for the higher dose group. Total withdrawals were significantly higher in the moderate and high dosage groups (OR=1.63 and 2.13 respectively), mostly due to increased adverse reactions (OR = 2.60 and 4.95 respectively), including renal and hematological abnormalities. Its efficacy appears to be similar to that of other disease modifying anti-rheumatic drugs (DMARDs), but with a significantly higher toxicity. Its effects on long-term functional status and radiological progression are not clear from this review.", "system1": "bart-xsum", "system2": "NAPSS", "ratings": [{"name": "readability", "type": "binary", "value": [0, 0, 0], "agg_value": 0, "agg_strategy": "majority"}]}
{"original": "Six trials were identified, with 425 patients randomized to D-penicillamine and 258 to placebo. A statistically significant benefit was observed for D-penicillamine when compared to placebo for all three-dose ranges and for most outcome measures including: tender joint counts, pain, physician's global assessments and ESR. The standardized weighted mean differences between treatment and placebo in moderate doses were -0.51 [95% CI -0.88, -0.14] for tender joint counts, -0.56 (95% CI -0.87, -0.26) for pain and -0.97 (95% CI -1.25, -0.70) for global assessment. The difference for ESR was -10.6 mm/hr. Similar results were observed for the higher dose group. Total withdrawals were significantly higher in the moderate and high dosage D-penicillamine groups (OR=1.63 and 2.13 respectively), mostly due to increased adverse reactions (OR = 2.60 and 4.95 respectively), including renal and hematological abnormalities. D-penicillamine appears to have a clinically and statistically significant benefit on the disease activity of patients with rheumatoid arthritis. Its efficacy appears to be similar to that of other disease modifying anti-rheumatic drugs (DMARDs), but with a significantly higher toxicity. Its effects on long-term functional status and radiological progression are not clear from this review.", "rating_type": "pairwise", "references": ["Penicillamine is a penicillin derived compound. Studies showed that this could be used to treat rheumatoid arthritis originally in 1950. It was frequently used in the past, but its use has declined with the increasing use of other disease modifying anti-rheumatic drugs (DMARDs), such as methotrexate. The purpose of this summary was to find out if penicillamine is helpful in the treatment of rheumatoid arthritis. Penicillamine was seen to be beneficial for all ranges of dosages for disease activity on tender joint pain, physician global assessment and sed rate. No major differences were observed between placebo and low dose penicillamine (<500 mg/day). For higher dosages, patients on penicillamine were twice as likely to withdraw than those receiving placebo 500 to <1000 mg/day. D-penicillamine appears be have a clinical and statistical benefit on the disease activity of patients with rheumatoid arthritis. Its benefit is similar to that of other such drugs, such as disease modifying anti-rheumatic drugs (DMARDs). More adverse reactions are seen in patients being treated with D-penicillamine."], "simplification1": "This review of trials found that D-penicillamine appears to have a clinically and statistically significant benefit on the disease activity of patients with rheumatoid arthritis. Its efficacy appears to be similar to that of other disease modifying anti-rheumatic drugs (DMARDs), but with a significantly higher toxicity. Its effects on long-term functional status and radiological progression are not clear from this review.", "simplification2": "This review of six trials found that D-penicillamine appears to be effective in improving the disease activity of rheumatoids. Its effects on long-term function and radiology are not clear. Its efficacy is similar to that of some other drugs, but with a higher risk of side-effects.", "system1": "bart-xsum", "system2": "Decoder", "ratings": [{"name": "readability", "type": "binary", "value": [1, 1, 1], "agg_value": 1, "agg_strategy": "majority"}]}
{"original": "Six trials were identified, with 425 patients randomized to D-penicillamine and 258 to placebo. A statistically significant benefit was observed for D-penicillamine when compared to placebo for all three-dose ranges and for most outcome measures including: tender joint counts, pain, physician's global assessments and ESR. The standardized weighted mean differences between treatment and placebo in moderate doses were -0.51 [95% CI -0.88, -0.14] for tender joint counts, -0.56 (95% CI -0.87, -0.26) for pain and -0.97 (95% CI -1.25, -0.70) for global assessment. The difference for ESR was -10.6 mm/hr. Similar results were observed for the higher dose group. Total withdrawals were significantly higher in the moderate and high dosage D-penicillamine groups (OR=1.63 and 2.13 respectively), mostly due to increased adverse reactions (OR = 2.60 and 4.95 respectively), including renal and hematological abnormalities. D-penicillamine appears to have a clinically and statistically significant benefit on the disease activity of patients with rheumatoid arthritis. Its efficacy appears to be similar to that of other disease modifying anti-rheumatic drugs (DMARDs), but with a significantly higher toxicity. Its effects on long-term functional status and radiological progression are not clear from this review.", "rating_type": "pairwise", "references": ["Penicillamine is a penicillin derived compound. Studies showed that this could be used to treat rheumatoid arthritis originally in 1950. It was frequently used in the past, but its use has declined with the increasing use of other disease modifying anti-rheumatic drugs (DMARDs), such as methotrexate. The purpose of this summary was to find out if penicillamine is helpful in the treatment of rheumatoid arthritis. Penicillamine was seen to be beneficial for all ranges of dosages for disease activity on tender joint pain, physician global assessment and sed rate. No major differences were observed between placebo and low dose penicillamine (<500 mg/day). For higher dosages, patients on penicillamine were twice as likely to withdraw than those receiving placebo 500 to <1000 mg/day. D-penicillamine appears be have a clinical and statistical benefit on the disease activity of patients with rheumatoid arthritis. Its benefit is similar to that of other such drugs, such as disease modifying anti-rheumatic drugs (DMARDs). More adverse reactions are seen in patients being treated with D-penicillamine."], "simplification1": "This review of trials found that D-penicillamine appears to have a clinically and statistically significant benefit on the disease activity of patients with rheumatoid arthritis. Its efficacy appears to be similar to that of other disease modifying anti-rheumatic drugs (DMARDs), but with a significantly higher toxicity. Its effects on long-term functional status and radiological progression are not clear from this review.", "simplification2": "This review found that D-penicillamine appears to be as good as other anti-rheumatic drugs and has the same effect on rheumatoid arthritis symptoms, although with more side effects.", "system1": "bart-xsum", "system2": "UL", "ratings": [{"name": "readability", "type": "binary", "value": [0, 1, 1], "agg_value": 1, "agg_strategy": "majority"}]}
{"original": "We included 24 studies with a total of 2166 participants, 23 of which provided data for meta-analysis. Thirteen studies had low risk of selection bias, five studies reported adequate blinding of outcome assessment and 15 studies had low risk of attrition bias. Seventeen studies that compared yoga versus no therapy provided moderate-quality evidence showing that yoga improved health-related quality of life (pooled SMD 0.22, 95% CI 0.04 to 0.40; 10 studies, 675 participants), reduced fatigue (pooled SMD -0.48, 95% CI -0.75 to -0.20; 11 studies, 883 participants) and reduced sleep disturbances in the short term (pooled SMD -0.25, 95% CI -0.40 to -0.09; six studies, 657 participants). The funnel plot for health-related quality of life was asymmetrical, favouring no therapy, and the funnel plot for fatigue was roughly symmetrical. This hints at overall low risk of publication bias. Yoga did not appear to reduce depression (pooled SMD -0.13, 95% CI -0.31 to 0.05; seven studies, 496 participants; low-quality evidence) or anxiety (pooled SMD -0.53, 95% CI -1.10 to 0.04; six studies, 346 participants; very low-quality evidence) in the short term and had no medium-term effects on health-related quality of life (pooled SMD 0.10, 95% CI -0.23 to 0.42; two studies, 146 participants; low-quality evidence) or fatigue (pooled SMD -0.04, 95% CI -0.36 to 0.29; two studies, 146 participants; low-quality evidence). Investigators reported no serious adverse events. Four studies that compared yoga versus psychosocial/educational interventions provided moderate-quality evidence indicating that yoga can reduce depression (pooled SMD -2.29, 95% CI -3.97 to -0.61; four studies, 226 participants), anxiety (pooled SMD -2.21, 95% CI -3.90 to -0.52; three studies, 195 participants) and fatigue (pooled SMD -0.90, 95% CI -1.31 to -0.50; two studies, 106 participants) in the short term. Very low-quality evidence showed no short-term effects on health-related quality of life (pooled SMD 0.81, 95% CI -0.50 to 2.12; two studies, 153 participants) or sleep disturbances (pooled SMD -0.21, 95% CI -0.76 to 0.34; two studies, 119 participants). No trial adequately reported safety-related data. Three studies that compared yoga versus exercise presented very low-quality evidence showing no short-term effects on health-related quality of life (pooled SMD -0.04, 95% CI -0.30 to 0.23; three studies, 233 participants) or fatigue (pooled SMD -0.21, 95% CI -0.66 to 0.25; three studies, 233 participants); no trial provided safety-related data. Moderate-quality evidence supports the recommendation of yoga as a supportive intervention for improving health-related quality of life and reducing fatigue and sleep disturbances when compared with no therapy, as well as for reducing depression, anxiety and fatigue, when compared with psychosocial/educational interventions. Very low-quality evidence suggests that yoga might be as effective as other exercise interventions and might be used as an alternative to other exercise programmes.", "rating_type": "pairwise", "references": ["We found 24 studies that involved 2166 women. Our evidence is current to January 2016. We found that women in 11 studies had completed surgery, chemotherapy and radiotherapy; women in three studies were currently undergoing chemotherapy; and women in five studies were currently undergoing radiotherapy. Women in the remaining five studies were either undergoing treatment or were not. Studies used a variety of questionnaires to assess quality of life, depression, fatigue and/or sleep disturbances. We found that yoga was more effective than no therapy in improving quality of life and reducing fatigue and sleep disturbances. We also found that yoga was better for reducing depression, anxiety and fatigue in women when compared with psychosocial or educational interventions such as counselling. We are fairly certain that these observed results are probably true. Yoga might be as effective as exercise in improving quality of life and reducing fatigue; we do not have enough data to be sure. Studies have poorly reported risks of yoga. However, we found no evidence of serious risks of yoga among women with a diagnosis of breast cancer. No studies have assessed effects of yoga in women given a diagnosis of breast cancer more than five years ago. Our findings indicate that women with a diagnosis of breast cancer can use yoga as supportive therapy for improving their quality of life and mental health, in addition to standard cancer treatments."], "simplification1": "We included 24 studies with a total of 2166 participants, 23 of which provided data for meta-analysis. Seventeen studies that compared yoga versus no therapy provided moderate-quality evidence showing that yoga improved health-related quality of life, reduced fatigue and sleep disturbances, and reduced sleep disturbances in the short term. Yoga did not appear to reduce depression, anxiety or fatigue, and had no short-term effects on health-quality of life or fatigue. No study reported on safety-related data. Four studies comparing yoga versus psychosocial/educational interventions provided moderate quality evidence indicating that yoga can reduce depression (four studies, 226 participants), anxiety (three studies, 195 participants) and fatigue (two studies, 106 participants). No study provided information on safety. Three studies compared yoga with exercise compared with no exercise. Evidence suggests that yoga might be as effective as other exercise interventions and might be used as an alternative to other exercise programmes. Investigators reported no serious adverse events. The quality of the evidence ranged from very low to moderate. This means that further research is likely to have an important impact on our confidence in the results.", "simplification2": "We included 24 studies with a total of 2166 participants. The evidence is current to January 2015. The review found that yoga can improve health-related quality of life and reduce fatigue and sleep disturbances when compared with no therapy, as well as for reducing depression, anxiety and fatigue, when compared to psychosocial/educational interventions. Yoga did not appear to reduce depression, sleep disturbances or anxiety in the short term. Yoga might be as effective as other exercise programmes and might be used as an alternative to other exercise. No serious adverse events were reported. The quality of the evidence was moderate for yoga versus no therapy and very low for yoga compared with psychosomatic interventions. The results of the review suggest that yoga might be an effective supportive intervention for improving health- related quality oflife and reducing fatigue and night-time sleep disturbances, as a supportive intervention when compared against no therapy. However, the quality of evidence was very low or low for other outcomes. The included studies did not adequately report safety-related data. The overall quality of this evidence was low or very low. The main limitations of the studies were the small number of participants and the small numbers of studies.", "system1": "bart-xsum", "system2": "Decoder", "ratings": [{"name": "readability", "type": "binary", "value": [0, 1, 0], "agg_value": 0, "agg_strategy": "majority"}]}
{"original": "We included 24 studies with a total of 2166 participants, 23 of which provided data for meta-analysis. Thirteen studies had low risk of selection bias, five studies reported adequate blinding of outcome assessment and 15 studies had low risk of attrition bias. Seventeen studies that compared yoga versus no therapy provided moderate-quality evidence showing that yoga improved health-related quality of life (pooled SMD 0.22, 95% CI 0.04 to 0.40; 10 studies, 675 participants), reduced fatigue (pooled SMD -0.48, 95% CI -0.75 to -0.20; 11 studies, 883 participants) and reduced sleep disturbances in the short term (pooled SMD -0.25, 95% CI -0.40 to -0.09; six studies, 657 participants). The funnel plot for health-related quality of life was asymmetrical, favouring no therapy, and the funnel plot for fatigue was roughly symmetrical. This hints at overall low risk of publication bias. Yoga did not appear to reduce depression (pooled SMD -0.13, 95% CI -0.31 to 0.05; seven studies, 496 participants; low-quality evidence) or anxiety (pooled SMD -0.53, 95% CI -1.10 to 0.04; six studies, 346 participants; very low-quality evidence) in the short term and had no medium-term effects on health-related quality of life (pooled SMD 0.10, 95% CI -0.23 to 0.42; two studies, 146 participants; low-quality evidence) or fatigue (pooled SMD -0.04, 95% CI -0.36 to 0.29; two studies, 146 participants; low-quality evidence). Investigators reported no serious adverse events. Four studies that compared yoga versus psychosocial/educational interventions provided moderate-quality evidence indicating that yoga can reduce depression (pooled SMD -2.29, 95% CI -3.97 to -0.61; four studies, 226 participants), anxiety (pooled SMD -2.21, 95% CI -3.90 to -0.52; three studies, 195 participants) and fatigue (pooled SMD -0.90, 95% CI -1.31 to -0.50; two studies, 106 participants) in the short term. Very low-quality evidence showed no short-term effects on health-related quality of life (pooled SMD 0.81, 95% CI -0.50 to 2.12; two studies, 153 participants) or sleep disturbances (pooled SMD -0.21, 95% CI -0.76 to 0.34; two studies, 119 participants). No trial adequately reported safety-related data. Three studies that compared yoga versus exercise presented very low-quality evidence showing no short-term effects on health-related quality of life (pooled SMD -0.04, 95% CI -0.30 to 0.23; three studies, 233 participants) or fatigue (pooled SMD -0.21, 95% CI -0.66 to 0.25; three studies, 233 participants); no trial provided safety-related data. Moderate-quality evidence supports the recommendation of yoga as a supportive intervention for improving health-related quality of life and reducing fatigue and sleep disturbances when compared with no therapy, as well as for reducing depression, anxiety and fatigue, when compared with psychosocial/educational interventions. Very low-quality evidence suggests that yoga might be as effective as other exercise interventions and might be used as an alternative to other exercise programmes.", "rating_type": "pairwise", "references": ["We found 24 studies that involved 2166 women. Our evidence is current to January 2016. We found that women in 11 studies had completed surgery, chemotherapy and radiotherapy; women in three studies were currently undergoing chemotherapy; and women in five studies were currently undergoing radiotherapy. Women in the remaining five studies were either undergoing treatment or were not. Studies used a variety of questionnaires to assess quality of life, depression, fatigue and/or sleep disturbances. We found that yoga was more effective than no therapy in improving quality of life and reducing fatigue and sleep disturbances. We also found that yoga was better for reducing depression, anxiety and fatigue in women when compared with psychosocial or educational interventions such as counselling. We are fairly certain that these observed results are probably true. Yoga might be as effective as exercise in improving quality of life and reducing fatigue; we do not have enough data to be sure. Studies have poorly reported risks of yoga. However, we found no evidence of serious risks of yoga among women with a diagnosis of breast cancer. No studies have assessed effects of yoga in women given a diagnosis of breast cancer more than five years ago. Our findings indicate that women with a diagnosis of breast cancer can use yoga as supportive therapy for improving their quality of life and mental health, in addition to standard cancer treatments."], "simplification1": "We included 24 studies with a total of 2166 participants, 23 of which provided data for meta-analysis. Seventeen studies that compared yoga versus no therapy provided moderate-quality evidence showing that yoga improved health-related quality of life, reduced fatigue and sleep disturbances, and reduced sleep disturbances in the short term. Yoga did not appear to reduce depression, anxiety or fatigue, and had no short-term effects on health-quality of life or fatigue. No study reported on safety-related data. Four studies comparing yoga versus psychosocial/educational interventions provided moderate quality evidence indicating that yoga can reduce depression (four studies, 226 participants), anxiety (three studies, 195 participants) and fatigue (two studies, 106 participants). No study provided information on safety. Three studies compared yoga with exercise compared with no exercise. Evidence suggests that yoga might be as effective as other exercise interventions and might be used as an alternative to other exercise programmes. Investigators reported no serious adverse events. The quality of the evidence ranged from very low to moderate. This means that further research is likely to have an important impact on our confidence in the results.", "simplification2": "We found 24 studies with a total of 2166 participants. Yoga was used in a range of positions (e.g. on the back, knee, back, back or both) and was compared with no therapy, or a psychosocial/educative treatment (where yoga is taught to change stress levels in a non-judgemental way), or exercise, or both. The evidence is up-to-date as of 19 February 2019. Yoga appears to be as good as no treatment for improving health-related quality of life, reducing tiredness and fatigue and anxiety and fatigue in the short-term. Yoga does not seem to be effective for the long-term, although it is not known if it is as effective as other treatments such as exercise. We do not know if yoga is better than other interventions such as weight-bearing or biofeedback. We did not find any studies that looked at the safety of yoga. The quality of the evidence ranged from low to very low. The main reasons for downgrades were that we did not have a high risk of bias (i.e. there was a high chance of arriving at the wrong conclusions because of the way the studies were designed and performed) and that many of the people in the study groups did not complete the study.", "system1": "bart-xsum", "system2": "UL", "ratings": [{"name": "readability", "type": "binary", "value": [0, 1, 0], "agg_value": 0, "agg_strategy": "majority"}]}
{"original": "We included 24 studies with a total of 2166 participants, 23 of which provided data for meta-analysis. Thirteen studies had low risk of selection bias, five studies reported adequate blinding of outcome assessment and 15 studies had low risk of attrition bias. Seventeen studies that compared yoga versus no therapy provided moderate-quality evidence showing that yoga improved health-related quality of life (pooled SMD 0.22, 95% CI 0.04 to 0.40; 10 studies, 675 participants), reduced fatigue (pooled SMD -0.48, 95% CI -0.75 to -0.20; 11 studies, 883 participants) and reduced sleep disturbances in the short term (pooled SMD -0.25, 95% CI -0.40 to -0.09; six studies, 657 participants). The funnel plot for health-related quality of life was asymmetrical, favouring no therapy, and the funnel plot for fatigue was roughly symmetrical. This hints at overall low risk of publication bias. Yoga did not appear to reduce depression (pooled SMD -0.13, 95% CI -0.31 to 0.05; seven studies, 496 participants; low-quality evidence) or anxiety (pooled SMD -0.53, 95% CI -1.10 to 0.04; six studies, 346 participants; very low-quality evidence) in the short term and had no medium-term effects on health-related quality of life (pooled SMD 0.10, 95% CI -0.23 to 0.42; two studies, 146 participants; low-quality evidence) or fatigue (pooled SMD -0.04, 95% CI -0.36 to 0.29; two studies, 146 participants; low-quality evidence). Investigators reported no serious adverse events. Four studies that compared yoga versus psychosocial/educational interventions provided moderate-quality evidence indicating that yoga can reduce depression (pooled SMD -2.29, 95% CI -3.97 to -0.61; four studies, 226 participants), anxiety (pooled SMD -2.21, 95% CI -3.90 to -0.52; three studies, 195 participants) and fatigue (pooled SMD -0.90, 95% CI -1.31 to -0.50; two studies, 106 participants) in the short term. Very low-quality evidence showed no short-term effects on health-related quality of life (pooled SMD 0.81, 95% CI -0.50 to 2.12; two studies, 153 participants) or sleep disturbances (pooled SMD -0.21, 95% CI -0.76 to 0.34; two studies, 119 participants). No trial adequately reported safety-related data. Three studies that compared yoga versus exercise presented very low-quality evidence showing no short-term effects on health-related quality of life (pooled SMD -0.04, 95% CI -0.30 to 0.23; three studies, 233 participants) or fatigue (pooled SMD -0.21, 95% CI -0.66 to 0.25; three studies, 233 participants); no trial provided safety-related data. Moderate-quality evidence supports the recommendation of yoga as a supportive intervention for improving health-related quality of life and reducing fatigue and sleep disturbances when compared with no therapy, as well as for reducing depression, anxiety and fatigue, when compared with psychosocial/educational interventions. Very low-quality evidence suggests that yoga might be as effective as other exercise interventions and might be used as an alternative to other exercise programmes.", "rating_type": "pairwise", "references": ["We found 24 studies that involved 2166 women. Our evidence is current to January 2016. We found that women in 11 studies had completed surgery, chemotherapy and radiotherapy; women in three studies were currently undergoing chemotherapy; and women in five studies were currently undergoing radiotherapy. Women in the remaining five studies were either undergoing treatment or were not. Studies used a variety of questionnaires to assess quality of life, depression, fatigue and/or sleep disturbances. We found that yoga was more effective than no therapy in improving quality of life and reducing fatigue and sleep disturbances. We also found that yoga was better for reducing depression, anxiety and fatigue in women when compared with psychosocial or educational interventions such as counselling. We are fairly certain that these observed results are probably true. Yoga might be as effective as exercise in improving quality of life and reducing fatigue; we do not have enough data to be sure. Studies have poorly reported risks of yoga. However, we found no evidence of serious risks of yoga among women with a diagnosis of breast cancer. No studies have assessed effects of yoga in women given a diagnosis of breast cancer more than five years ago. Our findings indicate that women with a diagnosis of breast cancer can use yoga as supportive therapy for improving their quality of life and mental health, in addition to standard cancer treatments."], "simplification1": "We included 24 studies with a total of 2166 participants, 23 of which provided data for meta-analysis. Seventeen studies that compared yoga versus no therapy provided moderate-quality evidence showing that yoga improved health-related quality of life, reduced fatigue and sleep disturbances, and reduced sleep disturbances in the short term. Yoga did not appear to reduce depression, anxiety or fatigue, and had no short-term effects on health-quality of life or fatigue. No study reported on safety-related data. Four studies comparing yoga versus psychosocial/educational interventions provided moderate quality evidence indicating that yoga can reduce depression (four studies, 226 participants), anxiety (three studies, 195 participants) and fatigue (two studies, 106 participants). No study provided information on safety. Three studies compared yoga with exercise compared with no exercise. Evidence suggests that yoga might be as effective as other exercise interventions and might be used as an alternative to other exercise programmes. Investigators reported no serious adverse events. The quality of the evidence ranged from very low to moderate. This means that further research is likely to have an important impact on our confidence in the results.", "simplification2": "We analyzed 24 studies with 2166 participants, and found that yoga can improve health-related quality of life, reduce fatigue, and decrease sleep disturbances compared to no therapy. It can also reduce depression, anxiety, and fatigue compared to psychosocial/educational interventions. However, yoga may not be more effective than other exercise programs. Overall, yoga is a recommended supportive intervention for improving health and well-being.", "system1": "bart-xsum", "system2": "GPT-4", "ratings": [{"name": "readability", "type": "binary", "value": [1, 1, 1], "agg_value": 1, "agg_strategy": "majority"}]}
{"original": "We included 24 studies with a total of 2166 participants, 23 of which provided data for meta-analysis. Thirteen studies had low risk of selection bias, five studies reported adequate blinding of outcome assessment and 15 studies had low risk of attrition bias. Seventeen studies that compared yoga versus no therapy provided moderate-quality evidence showing that yoga improved health-related quality of life (pooled SMD 0.22, 95% CI 0.04 to 0.40; 10 studies, 675 participants), reduced fatigue (pooled SMD -0.48, 95% CI -0.75 to -0.20; 11 studies, 883 participants) and reduced sleep disturbances in the short term (pooled SMD -0.25, 95% CI -0.40 to -0.09; six studies, 657 participants). The funnel plot for health-related quality of life was asymmetrical, favouring no therapy, and the funnel plot for fatigue was roughly symmetrical. This hints at overall low risk of publication bias. Yoga did not appear to reduce depression (pooled SMD -0.13, 95% CI -0.31 to 0.05; seven studies, 496 participants; low-quality evidence) or anxiety (pooled SMD -0.53, 95% CI -1.10 to 0.04; six studies, 346 participants; very low-quality evidence) in the short term and had no medium-term effects on health-related quality of life (pooled SMD 0.10, 95% CI -0.23 to 0.42; two studies, 146 participants; low-quality evidence) or fatigue (pooled SMD -0.04, 95% CI -0.36 to 0.29; two studies, 146 participants; low-quality evidence). Investigators reported no serious adverse events. Four studies that compared yoga versus psychosocial/educational interventions provided moderate-quality evidence indicating that yoga can reduce depression (pooled SMD -2.29, 95% CI -3.97 to -0.61; four studies, 226 participants), anxiety (pooled SMD -2.21, 95% CI -3.90 to -0.52; three studies, 195 participants) and fatigue (pooled SMD -0.90, 95% CI -1.31 to -0.50; two studies, 106 participants) in the short term. Very low-quality evidence showed no short-term effects on health-related quality of life (pooled SMD 0.81, 95% CI -0.50 to 2.12; two studies, 153 participants) or sleep disturbances (pooled SMD -0.21, 95% CI -0.76 to 0.34; two studies, 119 participants). No trial adequately reported safety-related data. Three studies that compared yoga versus exercise presented very low-quality evidence showing no short-term effects on health-related quality of life (pooled SMD -0.04, 95% CI -0.30 to 0.23; three studies, 233 participants) or fatigue (pooled SMD -0.21, 95% CI -0.66 to 0.25; three studies, 233 participants); no trial provided safety-related data. Moderate-quality evidence supports the recommendation of yoga as a supportive intervention for improving health-related quality of life and reducing fatigue and sleep disturbances when compared with no therapy, as well as for reducing depression, anxiety and fatigue, when compared with psychosocial/educational interventions. Very low-quality evidence suggests that yoga might be as effective as other exercise interventions and might be used as an alternative to other exercise programmes.", "rating_type": "pairwise", "references": ["We found 24 studies that involved 2166 women. Our evidence is current to January 2016. We found that women in 11 studies had completed surgery, chemotherapy and radiotherapy; women in three studies were currently undergoing chemotherapy; and women in five studies were currently undergoing radiotherapy. Women in the remaining five studies were either undergoing treatment or were not. Studies used a variety of questionnaires to assess quality of life, depression, fatigue and/or sleep disturbances. We found that yoga was more effective than no therapy in improving quality of life and reducing fatigue and sleep disturbances. We also found that yoga was better for reducing depression, anxiety and fatigue in women when compared with psychosocial or educational interventions such as counselling. We are fairly certain that these observed results are probably true. Yoga might be as effective as exercise in improving quality of life and reducing fatigue; we do not have enough data to be sure. Studies have poorly reported risks of yoga. However, we found no evidence of serious risks of yoga among women with a diagnosis of breast cancer. No studies have assessed effects of yoga in women given a diagnosis of breast cancer more than five years ago. Our findings indicate that women with a diagnosis of breast cancer can use yoga as supportive therapy for improving their quality of life and mental health, in addition to standard cancer treatments."], "simplification1": "We included 24 studies with a total of 2166 participants, 23 of which provided data for meta-analysis. Seventeen studies that compared yoga versus no therapy provided moderate-quality evidence showing that yoga improved health-related quality of life, reduced fatigue and sleep disturbances, and reduced sleep disturbances in the short term. Yoga did not appear to reduce depression, anxiety or fatigue, and had no short-term effects on health-quality of life or fatigue. No study reported on safety-related data. Four studies comparing yoga versus psychosocial/educational interventions provided moderate quality evidence indicating that yoga can reduce depression (four studies, 226 participants), anxiety (three studies, 195 participants) and fatigue (two studies, 106 participants). No study provided information on safety. Three studies compared yoga with exercise compared with no exercise. Evidence suggests that yoga might be as effective as other exercise interventions and might be used as an alternative to other exercise programmes. Investigators reported no serious adverse events. The quality of the evidence ranged from very low to moderate. This means that further research is likely to have an important impact on our confidence in the results.", "simplification2": "We included 24 studies with a total of 2166 participants, 23 of which provided data for meta-analysis. Thirteen studies had low risk of selection bias, five studies reported adequate blinding of outcome assessment and 15 studies had no attrition bias. Moderate-quality evidence showed that yoga improved health-related quality of life (10 studies, 675 participants), reduced fatigue (11 studies, 883 participants) and reduced sleep disturbances in the short term. Yoga did not appear to reduce depression (seven studies, 496 participants), anxiety (three studies, 195 participants) or fatigue (two studies, 146 participants). Three studies that compared yoga versus exercise showed no short-term effects on health- related quality of lives or fatigue or sleep disturbances. Very low-quality quality evidence showed no effect of yoga on depression, anxiety or fatigue. No trial adequately reported safety-related data. Four studies comparing yoga versus psychosocial/educational interventions provided moderate- quality evidence indicating that yoga can reduce depression and anxiety (four studies, 226 participants), fatigue and sleep disturbances (Two studies, 106 participants). Very low quality evidence suggests that yoga might be as effective as other exercise interventions and might be used as an alternative to other exercise programmes. Investigators reported no serious adverse events. The quality of the evidence ranged from moderate to very low.", "system1": "bart-xsum", "system2": "NAPSS", "ratings": [{"name": "readability", "type": "binary", "value": [0, 0, 0], "agg_value": 0, "agg_strategy": "majority"}]}
{"original": "We found nine eligible RCTs including 593 infants in total. These trials compared responsive with scheduled interval regimens in preterm infants in the transition phase from intragastric tube to oral feeding. The trials were generally small and contained various methodological weaknesses including lack of blinding and incomplete assessment of all randomised participants. Meta-analyses, although limited by data quality and availability, suggest that responsive feeding results in slightly slower rates of weight gain (MD \u22121.36, 95% CI \u22122.44 to \u22120.29 g/kg/day), and provide some evidence that responsive feeding reduces the time taken for infants to transition from enteral tube to oral feeding (MD \u22125.53, 95% CI \u22126.80 to \u22124.25 days). GRADE assessments indicated low quality of evidence. The importance of this finding is uncertain as the trials did not find a strong or consistent effect on the duration of hospitalisation. None of the included trials reported any parent, caregiver, or staff views. Overall, the data do not provide strong or consistent evidence that responsive feeding affects important outcomes for preterm infants or their families. Some (low quality) evidence exists that preterm infants fed in response to feeding and satiation cues achieve full oral feeding earlier than infants fed prescribed volumes at scheduled intervals. This finding should be interpreted cautiously because of methodological weaknesses in the included trials. A large RCT would be needed to confirm this finding and to determine if responsive feeding of preterm infants affects other important outcomes.", "rating_type": "pairwise", "references": ["We searched for all available evidence up to January 2016. We found nine eligible randomised controlled trials (including a total of 593 infants) that examined whether feeding preterm infants in response to their own feeding and satiation cues (sometimes called 'demand' feeding) is better than feeding set volumes of milk at predefined intervals. These trials compared responsive with scheduled interval regimens in preterm infants in the transition phase from intragastric tube to oral feeding. Although the trials were generally small and most had some methodological weaknesses, analysis suggests that responsive feeding results in slightly slower rates of weight gain and reduces the time taken for infants to transition from enteral tube to oral feeding. The quality of this evidence is low, and the importance of this finding is uncertain as the trials did not find a strong or consistent effect on the length of hospitalisation. None of the included trials reported any parent, caregiver, or staff views. This Cochrane review does not provide strong or consistent evidence that responsive feeding improves outcomes for preterm infants or their families. Responsive feeding might help infants transition more quickly to oral feeding, but more randomised controlled trials would be needed to confirm this finding."], "simplification1": "We found nine eligible randomised controlled trials (RCTs) including 593 infants in total. These trials compared responsive feeding with scheduled interval regimens in preterm infants in the transition phase from intragastric tube feeding to oral feeding. The trials were generally small and contained various methodological weaknesses including lack of blinding and incomplete assessment of all randomised participants. Meta-analyses, although limited by data quality and availability, suggest that responsive feeding results in slightly slower rates of weight gain (MD \u22121.36, 95% CI \u22122.44 to \u22120.29 g/kg/day), and provide some evidence that responsive feeds reduce the time taken for infants to transition from enteral tube to oral feeds (MD 5.53, 95%, CI \u22126.80 to \u22124.25 days). GRADE assessments indicated low quality of evidence. The importance of this finding is uncertain as the trials did not find a strong or consistent effect on the duration of hospitalisation. None of the included trials reported any parent, caregiver, or staff views. Overall, the data do not provide strong evidence thatresponsive feeding affects important outcomes for preterm babies or their families. Some (low quality) evidence exists that infants fed in response to feeding and satiation cues achieve full oral feeding earlier than infants fed prescribed volumes at scheduled intervals. This finding should be interpreted cautiously because of methodological weaknesses in the included studies.", "simplification2": "We found nine randomised controlled trials (RCTs) including 593 infants in total. The trials were generally small and contained various methodological weaknesses including lack of blinding and incomplete assessment of all randomised participants. None of the included trials reported any parent, caregiver, or staff views. These trials compared responsive feeding with scheduled interval regimens in preterm infants in the transition phase from intragastric tube to oral feeding. Meta-analyses, although limited by data quality and availability, suggest that responsive feeding results in slightly slower rates of weight gain (1.36 g/kg/day), and provide some evidence thatresponsive feeding reduces the time taken for infants to transition from an enteral tube to an oral tube (5.53 days). The importance of this finding is uncertain as the trials did not find a strong or consistent effect on the duration of hospitalisation. Overall, the data do not provide strong evidence to support the use of responsive feeding. Some (low quality) evidence exists that infants fed in response to feeding and satiation cues achieve full oral feeding earlier than infants fed prescribed volumes at scheduled intervals. This finding should be interpreted cautiously because of methodological weaknesses in included trials. A large RCT would be needed to confirm this finding and to determine if responsive feeding affects other important outcomes. GRADE assessments indicated low quality of evidence.", "system1": "bart-xsum", "system2": "NAPSS", "ratings": [{"name": "readability", "type": "binary", "value": [1, 0, 0], "agg_value": 0, "agg_strategy": "majority"}]}
{"original": "We found nine eligible RCTs including 593 infants in total. These trials compared responsive with scheduled interval regimens in preterm infants in the transition phase from intragastric tube to oral feeding. The trials were generally small and contained various methodological weaknesses including lack of blinding and incomplete assessment of all randomised participants. Meta-analyses, although limited by data quality and availability, suggest that responsive feeding results in slightly slower rates of weight gain (MD \u22121.36, 95% CI \u22122.44 to \u22120.29 g/kg/day), and provide some evidence that responsive feeding reduces the time taken for infants to transition from enteral tube to oral feeding (MD \u22125.53, 95% CI \u22126.80 to \u22124.25 days). GRADE assessments indicated low quality of evidence. The importance of this finding is uncertain as the trials did not find a strong or consistent effect on the duration of hospitalisation. None of the included trials reported any parent, caregiver, or staff views. Overall, the data do not provide strong or consistent evidence that responsive feeding affects important outcomes for preterm infants or their families. Some (low quality) evidence exists that preterm infants fed in response to feeding and satiation cues achieve full oral feeding earlier than infants fed prescribed volumes at scheduled intervals. This finding should be interpreted cautiously because of methodological weaknesses in the included trials. A large RCT would be needed to confirm this finding and to determine if responsive feeding of preterm infants affects other important outcomes.", "rating_type": "pairwise", "references": ["We searched for all available evidence up to January 2016. We found nine eligible randomised controlled trials (including a total of 593 infants) that examined whether feeding preterm infants in response to their own feeding and satiation cues (sometimes called 'demand' feeding) is better than feeding set volumes of milk at predefined intervals. These trials compared responsive with scheduled interval regimens in preterm infants in the transition phase from intragastric tube to oral feeding. Although the trials were generally small and most had some methodological weaknesses, analysis suggests that responsive feeding results in slightly slower rates of weight gain and reduces the time taken for infants to transition from enteral tube to oral feeding. The quality of this evidence is low, and the importance of this finding is uncertain as the trials did not find a strong or consistent effect on the length of hospitalisation. None of the included trials reported any parent, caregiver, or staff views. This Cochrane review does not provide strong or consistent evidence that responsive feeding improves outcomes for preterm infants or their families. Responsive feeding might help infants transition more quickly to oral feeding, but more randomised controlled trials would be needed to confirm this finding."], "simplification1": "We found nine eligible randomised controlled trials (RCTs) including 593 infants in total. These trials compared responsive feeding with scheduled interval regimens in preterm infants in the transition phase from intragastric tube feeding to oral feeding. The trials were generally small and contained various methodological weaknesses including lack of blinding and incomplete assessment of all randomised participants. Meta-analyses, although limited by data quality and availability, suggest that responsive feeding results in slightly slower rates of weight gain (MD \u22121.36, 95% CI \u22122.44 to \u22120.29 g/kg/day), and provide some evidence that responsive feeds reduce the time taken for infants to transition from enteral tube to oral feeds (MD 5.53, 95%, CI \u22126.80 to \u22124.25 days). GRADE assessments indicated low quality of evidence. The importance of this finding is uncertain as the trials did not find a strong or consistent effect on the duration of hospitalisation. None of the included trials reported any parent, caregiver, or staff views. Overall, the data do not provide strong evidence thatresponsive feeding affects important outcomes for preterm babies or their families. Some (low quality) evidence exists that infants fed in response to feeding and satiation cues achieve full oral feeding earlier than infants fed prescribed volumes at scheduled intervals. This finding should be interpreted cautiously because of methodological weaknesses in the included studies.", "simplification2": "We found nine studies with 593 infants comparing responsive and scheduled feeding in preterm infants transitioning from tube to oral feeding. The studies had some weaknesses and limited data quality. Results suggest that responsive feeding may lead to slightly slower weight gain and faster transition to oral feeding, but the evidence is of low quality. The impact of this finding is unclear, as there was no strong effect on hospital stay duration. No parent or caregiver opinions were reported. Overall, there is no strong evidence that responsive feeding affects important outcomes for preterm infants or their families. Some low-quality evidence suggests that responsive feeding may help infants reach full oral feeding sooner. However,", "system1": "bart-xsum", "system2": "GPT-4", "ratings": [{"name": "readability", "type": "binary", "value": [0, 1, 1], "agg_value": 1, "agg_strategy": "majority"}]}
{"original": "We found nine eligible RCTs including 593 infants in total. These trials compared responsive with scheduled interval regimens in preterm infants in the transition phase from intragastric tube to oral feeding. The trials were generally small and contained various methodological weaknesses including lack of blinding and incomplete assessment of all randomised participants. Meta-analyses, although limited by data quality and availability, suggest that responsive feeding results in slightly slower rates of weight gain (MD \u22121.36, 95% CI \u22122.44 to \u22120.29 g/kg/day), and provide some evidence that responsive feeding reduces the time taken for infants to transition from enteral tube to oral feeding (MD \u22125.53, 95% CI \u22126.80 to \u22124.25 days). GRADE assessments indicated low quality of evidence. The importance of this finding is uncertain as the trials did not find a strong or consistent effect on the duration of hospitalisation. None of the included trials reported any parent, caregiver, or staff views. Overall, the data do not provide strong or consistent evidence that responsive feeding affects important outcomes for preterm infants or their families. Some (low quality) evidence exists that preterm infants fed in response to feeding and satiation cues achieve full oral feeding earlier than infants fed prescribed volumes at scheduled intervals. This finding should be interpreted cautiously because of methodological weaknesses in the included trials. A large RCT would be needed to confirm this finding and to determine if responsive feeding of preterm infants affects other important outcomes.", "rating_type": "pairwise", "references": ["We searched for all available evidence up to January 2016. We found nine eligible randomised controlled trials (including a total of 593 infants) that examined whether feeding preterm infants in response to their own feeding and satiation cues (sometimes called 'demand' feeding) is better than feeding set volumes of milk at predefined intervals. These trials compared responsive with scheduled interval regimens in preterm infants in the transition phase from intragastric tube to oral feeding. Although the trials were generally small and most had some methodological weaknesses, analysis suggests that responsive feeding results in slightly slower rates of weight gain and reduces the time taken for infants to transition from enteral tube to oral feeding. The quality of this evidence is low, and the importance of this finding is uncertain as the trials did not find a strong or consistent effect on the length of hospitalisation. None of the included trials reported any parent, caregiver, or staff views. This Cochrane review does not provide strong or consistent evidence that responsive feeding improves outcomes for preterm infants or their families. Responsive feeding might help infants transition more quickly to oral feeding, but more randomised controlled trials would be needed to confirm this finding."], "simplification1": "We found nine eligible randomised controlled trials (RCTs) including 593 infants in total. These trials compared responsive feeding with scheduled interval regimens in preterm infants in the transition phase from intragastric tube feeding to oral feeding. The trials were generally small and contained various methodological weaknesses including lack of blinding and incomplete assessment of all randomised participants. Meta-analyses, although limited by data quality and availability, suggest that responsive feeding results in slightly slower rates of weight gain (MD \u22121.36, 95% CI \u22122.44 to \u22120.29 g/kg/day), and provide some evidence that responsive feeds reduce the time taken for infants to transition from enteral tube to oral feeds (MD 5.53, 95%, CI \u22126.80 to \u22124.25 days). GRADE assessments indicated low quality of evidence. The importance of this finding is uncertain as the trials did not find a strong or consistent effect on the duration of hospitalisation. None of the included trials reported any parent, caregiver, or staff views. Overall, the data do not provide strong evidence thatresponsive feeding affects important outcomes for preterm babies or their families. Some (low quality) evidence exists that infants fed in response to feeding and satiation cues achieve full oral feeding earlier than infants fed prescribed volumes at scheduled intervals. This finding should be interpreted cautiously because of methodological weaknesses in the included studies.", "simplification2": "We found nine randomised controlled trials (RCTs) involving 593 preterm babies. We found that some (but not all) RCTs showed a trend to a faster rate of weight gain in preterm infants who had been on an intagastric tube compared with those who had received a normal feed. We did not find strong (or consistent) evidence that the rate of growth or development of preterm children who had responded to a restart of their own feeding was different from those who did not. We are uncertain as to whether this is the case as the quality of the evidence was low. We identified a need for a large RCT to confirm this finding and to find out if the rates of growth and development of these preterm newborns are the same as those who are not. None of the trials reported any parent, caregiver, or staff views. Overall, we do not have strong (if any) results for the primary outcomes of this review.", "system1": "bart-xsum", "system2": "UL", "ratings": [{"name": "readability", "type": "binary", "value": [0, 1, 1], "agg_value": 1, "agg_strategy": "majority"}]}
